what is glp-1 for vs. GLP-1 + GIP: What's the Difference your Metabolism? Understanding semaglutide (GLP-1 RA): Are
Description
The Glucagon-like Peptide-1 Agonists Market worth USD 52.30 billion in 2026 is growing at a CAGR of 13.26% to reach USD 97.45 billion by 2031
The GLP-1 Kitchen: A Cookbook for Living Well on Weight Loss Medications [Escobar, Dr
Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027
Approval isnt guaranteed but the direction of metabolic medicine is now obvious
Michael Greger explores the science behind these medications and gives us the answers we need
